1. Home
  2. LENZ

as 07-24-2024 4:00pm EST

$
-
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Medicinal Chemicals and Botanical Products

Nasdaq

LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.

Founded: 2019 Country:
Canada
Canada
Employees: N/A City: DEL MAR
Market Cap: 396.0M IPO Year: 2021
Target Price: $31.33 AVG Volume (30 days): 184.4K
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -15.85 EPS Growth: N/A
52 Week Low/High: $2.01 - $24.59 Next Earning Date: 05-08-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

LENZ Daily Stock ML Predictions

Stock Insider Trading Activity of LENZ Therapeutics Inc. Common Stock (LENZ)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Chevallard Daniel R. LENZ Chief Financial Officer May 14 '24 Buy $15.68 3,188 $49,987.84 3,188 SEC Form 4
MCCOLLUM JAMES W LENZ Director May 13 '24 Buy $15.99 31,332 $501,092.68 525,565 SEC Form 4
RA CAPITAL MANAGEMENT, L.P. LENZ Director10% Owner Mar 21 '24 Buy $15.03 64,971 $976,514.13 694,755 SEC Form 4
RA CAPITAL MANAGEMENT, L.P. LENZ Director10% Owner Mar 21 '24 Buy $15.03 933,038 $14,023,561.14 3,319,339 SEC Form 4

Share on Social Networks: